Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Reports 3Q Revenues Up

NEW YORK, Nov. 5, (GenomeWeb News) - South San Francisco-based Exelixis reported $12.4 million in revenues for the third quarter ending Sept. 30, up over revenues of $10.4 million for the same period in 2002.


The company reported a net loss of approximately $25 million, up over a net loss of $23 million for the third quarter in 2002.


The company had cash, cash equivalents, short-term investments, and restricted cash of approximately $219 million as of Sept. 30, compared to $222 million at December 31, 2002.


Research and development expenses for the quarter ended September 30, 2003 were $32 million compared to $29 million for the same quarter in 2002.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.